Valiltramiprosate

ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease[2].

Product Specifications

CAS Number

[1034190-08-3]

Product Name Alternative

ALZ-801

UNSPSC

12352211

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/alz-801.html

Purity

98.83

Solubility

H2O : 30 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(CCCNC([C@@H](N)C(C)C)=O)(O)=O

Molecular Formula

C8H18N2O4S

Molecular Weight

238.30

References & Citations

[1]John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32 (9) : 849–861.|[2]Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57 (3) :315-333.